ID   Pre-Alp
AC   CVCL_IU85
SY   PRE-ALP; PreALP
DR   Cosmic; 2491073
DR   Wikidata; Q54948341
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=7919343;
RX   PubMed=8464241;
RX   PubMed=9067587;
RX   PubMed=29786757;
RX   PubMed=35124168;
CC   Doubling time: ~24 hours (PubMed=8464241).
CC   Sequence variation: Gene fusion; HGNC; HGNC:8632; PBX1 + HGNC; HGNC:11633; TCF3; Name(s)=TCF3-PBX1, E2A-PBX1 (PubMed=29786757; PubMed=35124168).
CC   Sequence variation: Mutation; HGNC; HGNC:7978; NR3C1; Simple; p.Arg23Lys (c.68G>A); ClinVar=VCV000351377; Zygosity=Heterozygous (PubMed=35124168).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C9140; Childhood B acute lymphoblastic leukemia
DI   NCIt; C80347; B acute lymphoblastic leukemia with t(1;19)(q23;p13.3) E2A-PBX1 (TCF3-PBX1)
DI   ORDO; Orphanet_585956; B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3)
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   6Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 19-12-24; Version: 10
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=7919343; DOI=10.1182/blood.V84.7.2253.2253;
RA   Renard N., Duvert V., Banchereau J., Saeland S.;
RT   "Interleukin-13 inhibits the proliferation of normal and leukemic
RT   human B-cell precursors.";
RL   Blood 84:2253-2260(1994).
//
RX   PubMed=8464241;
RA   Pandrau-Garcia D., Frances V., Martinez-Valdez H., Pages M.-P.,
RA   Manel A.-M., Philippe N., Banchereau J., Saeland S.;
RT   "Characterization of a t(1;19) pre-B acute lymphoblastic leukemia
RT   (ALL) cell line which proliferates in response to IL-7.";
RL   Leukemia 7:635-642(1993).
//
RX   PubMed=9067587; DOI=10.1038/sj.leu.2400571;
RA   Uphoff C.C., MacLeod R.A.F., Denkmann S.A., Golub T.R., Borkhardt A.,
RA   Janssen J.W.G., Drexler H.G.;
RT   "Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in
RT   human early B-lineage leukemia cell lines.";
RL   Leukemia 11:441-447(1997).
//
RX   PubMed=29786757; DOI=10.1007/s12185-018-2474-7;
RA   Tomoyasu C., Imamura T., Tomii T., Yano M., Asai D., Goto H.,
RA   Shimada A., Sanada M., Iwamoto S., Takita J., Minegishi M., Inukai T.,
RA   Sugita K., Hosoi H.;
RT   "Copy number abnormality of acute lymphoblastic leukemia cell lines
RT   based on their genetic subtypes.";
RL   Int. J. Hematol. 108:312-318(2018).
//
RX   PubMed=35124168; DOI=10.1016/j.jsbmb.2022.106068;
RA   Tamai M., Kasai S., Akahane K., Thu T.N., Kagami K., Komatsu C.,
RA   Abe M., Watanabe A., Goi K., Miyake K., Inaba T., Takita J., Goto H.,
RA   Minegishi M., Iwamoto S., Sugita K., Inukai T.;
RT   "Glucocorticoid receptor gene mutations confer glucocorticoid
RT   resistance in B-cell precursor acute lymphoblastic leukemia.";
RL   J. Steroid Biochem. Mol. Biol. 218:106068.1-106068.12(2022).
//